GET DAILY SIGNALSSINTX Technologies (SINT) Delivers Strong Q3 Performance with +953% Revenue Growth
Key Takeaways
- SINTX Technologies reported third-quarter 2026 revenue of approximately $2.2 million, up 953% from $208,000 a year earlier, driven by aerospace technical manufacturing sales.
- Gross profit climbed to roughly $1.4 million, with gross margin expanding to 62% from 45% in the prior-year quarter.
- Net loss narrowed 55% to about $1.6 million, while operating expenses declined 13% to approximately $3.0 million.
- GAAP net loss per share came in at $0.24, narrower than analyst consensus estimates, with revenue topping expectations.
- The company regained compliance with Nasdaq's minimum stockholders' equity requirement and received roughly $2.0 million from the exercise of Class B warrants.
Earnings Context and Why It Matters
SINTX Technologies is an advanced biomaterials and ceramics company commercializing proprietary silicon nitride across medical and industrial applications. For years, the company has operated with minimal revenue and persistent losses, making each quarterly report a test of whether its manufacturing and commercialization strategy can translate into sustained financial progress. The third quarter of 2026 carries added weight because it represents the first full quarter reflecting shipments against the more than $3.2 million in contract manufacturing purchase orders announced in June. I’m watching this closely to determine whether the company can convert order flow into recognized revenue, expand gross margin, and reduce cash burn as it pivots toward commercial scale.
Reported Results
For the third quarter ended September 30, 2026, SINTX reported total revenue of approximately $2.2 million, a 953% increase from $208,000 in the prior-year period. Product revenue was $2.1 million, up from $150,000 a year earlier, with the growth driven primarily by aerospace technical manufacturing sales to Fortune 500 customers. Grant and contract revenue was $100,000, compared with $58,000 in the prior-year quarter.
Gross profit rose to approximately $1.4 million from $93,000 a year ago, and gross margin expanded to 62% from 45%, helped by pricing adjustments, favorable product mix, and higher production volumes. Total operating expenses fell 13% to about $3.0 million, and the net loss narrowed 55% to roughly $1.6 million from $3.5 million. On a per-share basis, the company posted a GAAP net loss of $0.24, narrower than the consensus estimate of about $0.34 per share, while revenue of $2.2 million topped the consensus estimate of roughly $0.9 million.
On the balance sheet, cash and cash equivalents stood at approximately $2.0 million at quarter-end, down from $4.1 million at the end of 2025, reflecting operating cash use and working capital investment. The company subsequently received about $2.0 million from the exercise of Class B warrants and regained compliance with Nasdaq's minimum stockholders' equity requirement. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Sentiment heading into the report had already improved after the company's October 1 preliminary announcement revealed $2.2 million in third-quarter revenue, far above its prior guidance range of $0.9 million to $1.1 million. The confirmed results reinforced that momentum, with revenue, gross margin, and the narrowed loss all exceeding consensus expectations. Still, investor interpretation remains measured: the company continues to report losses and ended the quarter with about $2.0 million in cash, underscoring ongoing liquidity and financing considerations. The regained Nasdaq listing compliance and the warrant exercise proceeds provided some balance-sheet relief, but execution risk around converting further purchase orders into recognized revenue remains a central focus for the market.
Forward Outlook and Key Factors to Monitor
The most important near-term catalyst is fourth-quarter revenue, where management reiterated a guidance range of approximately $1.0 million to $1.3 million. Because the timing and size of customer orders can cause meaningful quarterly swings, investors should track whether the company continues converting its remaining contract manufacturing purchase orders into recognized revenue on schedule.
Margin sustainability is another key factor. The 62% gross margin reflected favorable mix, pricing, and production volumes, but management has cautioned that margins can vary from quarter to quarter based on product mix and demand. Watching whether margins hold as the industrial business scales will help clarify the durability of recent improvements.
Finally, liquidity and financing remain central to the story. With cash of roughly $2.0 million at quarter-end and ongoing operating losses, the company's ability to fund working capital and commercialization without overly dilutive capital raises is a critical monitorable. Progress on the SiNAPTIC Foot & Ankle Osteotomy Wedge System and the silicon nitride-treated medical textile studies also represent longer-term growth avenues worth following.
Using AI Tools for Deeper Analysis
In my view, tools like Tickeron’s AI Screener can help investors quickly compare SINTX against peers on fundamentals and technical signals. From what I see, this kind of filtering adds useful context when evaluating smaller companies navigating commercialization phases.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SINT sees MACD Histogram just turned negative
SINT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 43 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SINT as a result. In 79 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
SINT moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SINT crossed bearishly below the 50-day moving average on October 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SINT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SINT entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SINT's RSI Oscillator exited the oversold zone, 36 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 59 cases where SINT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +12.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where SINT advanced for three days, in 170 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SINT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.263) is normal, around the industry mean (4.115). P/E Ratio (-0.299) is within average values for comparable stocks, (1.586). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.057) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. SINT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SINT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of spinal and reconstructive orthopedic devices
Industry MedicalNursingServices
Advertisement